Design a malaria vaccine by selecting lifecycle targets, dosing regimens, and adjuvant formulations. Observe within-host immunity dynamics and the evolution of antigenic resistance.
R&D Budget
$500M
remaining / $500M
Spent
$0M
development cost
Sim Horizon
10 yrs
post-deployment
Step 1 — Select lifecycle targets (multi-select)
✓
🦟
Pre-Erythrocytic
CSP · TRAP · LSA-1
Targets sporozoites and hepatocytes. Blocks infection before blood-stage parasitemia. Mechanism: anti-CSP antibodies intercept sporozoites in transit to liver.
Max efficacy
~75%
Resistance rate
t½≈2.5yr
Base cost
$80M
Dev. time
6 yr
✓
🩸
Blood Stage
AMA1 · MSP1 · RH5
Targets merozoites and intraerythrocytic parasites. Reduces peak parasitemia and severe disease. High antigenic diversity — polymorphic escape common.
Max efficacy
~55%
Resistance rate
t½≈1.5yr
Base cost
$100M
Dev. time
8 yr
✓
🦠
Transmission Blocking
Pfs25 · Pfs230 · Pfs48/45
Targets gametocytes and mosquito midgut stages. No direct individual benefit — acts altruistically at population level. Very slow resistance evolution.
VSG resistance modifier
1 = full susceptibility to escape0.80
Cost Breakdown
Stage targets$0M
Dosing regimen$0M
Adjuvant / formulation$0M
Antigen breadth$0M
Booster programme$0M
TOTAL R&D$0M
Peak Ab Titre
—
IgG arbitrary units
Peak Parasitemia
—
% reduction vs control
Efficacy at Yr 5
—
vaccine protected fraction
Resistance t½
—
years to 50% escape allele
Antibody Titre & Parasite Dynamics
Within-host · Days 0–365
Vaccine Efficacy Decay & Resistance Evolution
Population level · Years 0–10
Resistance Evolution Timeline
by target stage
Deploy a vaccine to see resistance projections.
Mechanistic Interpretation
Select lifecycle targets and configure your vaccine design parameters, then press Deploy Vaccine to simulate within-host immunity kinetics and population-level resistance evolution.